Strategy for Treating the Gastric Cancer: A Systematic Review and Meta-analysis
<strong>Background and aim:</strong> Contemporary approaches to treat the stage IV patients could be generally divide into 5 groups of the palliative gastrectomy, radiotherapy, chemotherapy, bypass, and gastric stent. The aim of the present systematic review and meta-analysis was evaluat...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
International Journal of Scientific Research in Dental and Medical Sciences (IJSRDMS),
2020-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <strong>Background and aim:</strong> Contemporary approaches to treat the stage IV patients could be generally divide into 5 groups of the palliative gastrectomy, radiotherapy, chemotherapy, bypass, and gastric stent. The aim of the present systematic review and meta-analysis was evaluate the overall survival to treat the stage IV gastric cancer (GC) on the basis of the distinct signs and prognosis.<br /> <strong>Materials and methods:</strong> MEDLINE, PubMed, Cochrane Library, Embase, ISI, google scholar have been utilized as the electronic data-bases for searching a systematic literature until 2019. Then, Endnote X9 that is one of software programs in the market has been applied to electronically manage the titles. Searches were performed with keywords, "Gastric cancer", "cancer"," Gastric"," Stage IV", "Radiotherapy" "Chemotherapy" , "Gastrectomy", "treatment of gastric cancer", "bypass". <br /> <strong>Results:</strong> A total of 150, 93, 21 studies respective abstracts and topics have been discovered in the course of manual and electronic searches in the internet. Finally, a total of 10 studies for Palliative gastrectomy, 5 studies for Chemotherapy and 3 studies for Radiotherapy required for this systematic review. <br /> <strong>Conclusion:</strong> According to the meta-analysis, palliative gastrectomy exhibited a statistically significant survival advantage for the patients with the untreatable developed GC. |
|---|---|
| Item Description: | 2676-5497 2676-5373 10.30485/ijsrdms.2020.215947.1033 |